Innocoll

ASHBURN, Va.,February 17^th, 2012 /PRNewswire/ –– Innocoll, Inc. announced that it has held an End-of-Phase 2 meeting with the FDA to present the results of the Phase 2 clinical studies completed for XaraColl^® and to discuss the proposed safety and efficacy studies to be conducted in Phase 3. XaraColl^® is being developed for postoperative analgesia and Innocoll plans to undertake its Phase 3 program in patients undergoing hernia repair. FDA agreed to the Phase 3 clinical studies that Innocoll proposed and confirmed that, if successful, those studies should be sufficient to support a future NDA submission.